Genprex Demonstrates Growth and Expansion Through Recent Achievements
Last genprex, inc earnings: 11/14 12:08 pm
Check Earnings Report
Company’s recent performance sets path for future milestones, commercialization AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced recent achievements the company has completed as a part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex™ immunogene therapy, to commercialization.These recent achievements are outlined in the company’s newly launched, interactive corporate timeline, which can be found on Genprex’s website.“Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth of our team to support these initatives,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “These accomplishments have set the stage for us to co
[Read more]
| Impact snapshot | Event time: | GNPX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
GNPX alerts
GNPX alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNPX alerts
High impacting Genprex, Inc news events
Weekly update
A roundup of the hottest topics
GNPX
News
- Genprex Announces $1.26 Million Registered Direct OfferingBusiness Wire
- Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung CancersBusiness Wire
- Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness MonthBusiness Wire
- Genprex to Present at the MicroCap Rodeo Investor ConferenceBusiness Wire
- Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry SupportBusiness Wire
- More
GNPX
SEC Filings
- 11/22/19 - Form 8-K
- 11/22/19 - Form D
- 11/22/19 - Form SC
- GNPX's page on the SEC website
- More